Trials / Unknown
UnknownNCT05075928
Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
SARS-COV-2 infection is responsible for a potentially severe primarily respiratory infection called COVID19. A large proportion of patients, in particular in severe forms, present with thrombotic manifestations (DVT, EP, stroke, thrombosis of dialysis circuits, etc.). A significant proportion is also a carrier of circulating anticoagulant (ACC or LA), making it possible to suggest a diagnosis of APS. This type of autoantibody results in a spontaneous prolongation of the TCA uncorrected by a control serum therefore is quickly diagnosed using standard hemostasis The objective of this study is to describe the diagnosis of thrombotic complications in COVID19 patients presenting a positive lupus anticoagulant type test (LA) or aPL and the associated clinical and biological elements that may have favored thrombosis.
Conditions
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2021-11-01
- Completion
- 2021-11-01
- First posted
- 2021-10-13
- Last updated
- 2021-12-01
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05075928. Inclusion in this directory is not an endorsement.